Results 91 to 100 of about 23,963 (194)

Multi‐Omics Analysis in Autoimmunity: Identification of MicroRNA Regulatory Networks and Cell‐Type‐Specific Dysregulations in Multiple Sclerosis and Type 1 Diabetes

MedComm, Volume 7, Issue 4, April 2026.
This study evaluates the expression of microRNAs (miRNAs) in three distinct immune subsets (CD14+ monocytes, neutrophils, and CD8+ T cells) in multiple sclerosis and type 1 diabetes, reporting the presence of unique alteration patterns. Our integrative multi‐omics analysis suggests that miRNAs play a pivotal role in the differentiation and migration of
Jacopo Ronchi, Roberta Rigolio, Davide Maria Trevisan, Angela Papagna, Angela Stabilini, Martina Gallinaro, Maria Letizia Fusco, Martina Gaia Cogo, Guido Cavaletti, Giovanni Malerba, Manuela Battaglia, Maria Foti   +11 more
wiley   +1 more source

A steric tethering approach enables palladium-catalysed C-H activation of primary amino alcohols. [PDF]

, 2015
Aliphatic primary amines are a class of chemical feedstock essential to the synthesis of higher-order nitrogen-containing molecules, commonly found in biologically active compounds and pharmaceutical agents.
A McNally, AD Ryabov, AJ Hickman, Benjamin Haffemayer, C Jia, CR Strader, D Garcia-Cuadrado, D-H Wang, DA Colby, Daniel Pla, EM Ferreira, EM Simmons, F Lovering, G He, GA Reichard, GT Kunkel, HML Davies, HML Davies, IAI Mkhalid, J Dupont, J Wencel-Delord, J Yamaguchi, J Yuan, J-Y Cho, Jonas Calleja, K Bera, K Godula, KJ Stowers, KM Engle, KSL Chan, L Ackermann, LV Desai, M Darabantu, M Wasa, M Wasa, Matthew J. Gaunt, MH Emmert, NR Deprez, NY Kozitsyna, O Daugulis, R Giri, R Giri, R Jazzar, S Gorelsky, S Li, S-Y Zhang, T Ishiyama, Timothy W. Gorman, TJ Donohoe, TW Lyons, VG Zaitsev, Victoriano Domingo, Y-H Zhang   +52 more
core   +3 more sources

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Brain health: time matters in multiple sclerosis [PDF]

, 2016
publisher: Elsevier articletitle: Brain health: time matters in multiple sclerosis journaltitle: Multiple Sclerosis and Related Disorders articlelink: http://dx.doi.org/10.1016/j.msard.2016.07.003 content_type: article copyright: © 2016 Oxford ...
Butzkueven, H, Dhib-Jalbut, S, Giovannoni, G, Hobart, J, Kobelt, G, Pepper, G, Sormani, MP, Thalheim, C, Traboulsee, A, Vollmer, T   +9 more
core   +2 more sources

Blood–Brain Barrier: Structure, Function, Diseases, and Drug Delivery Systems

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract illustrates how blood–brain barrier‐targeted nanomedicine integrates diverse nanocarrier platforms with mechanism‐based therapeutic strategies to overcome delivery barriers in ischemic stroke, enabling targeted modulation of oxidative stress, inflammation, excitotoxicity, and neuronal survival.
Yanan He, Mengyao Qu, Lu Yu, Lipeng He, Yixun Lu, Jin Hong, Miao Sun, Huikai Yang, Weidong Mi, Hang Guo, Yulong Ma   +10 more
wiley   +1 more source

Lipid Metabolism and Obesity in Early Life: Drivers of Chronic Lung Disease From Development to Adulthood

Molecular Nutrition &Food Research, Volume 70, Issue 7, 15 April 2026.
Metabolic and nutritional stressors are a growing global health concern. This review discusses how obesity, lipids, and lipid derivatives influence lung development, homeostasis, and chronic lung disease progression, highlighting roles of alveolar surfactant and sphingolipids.
Jaco Selle, Natascha Mierswa, Leon Saschin, Jana Niehues, Jörg Dötsch, Eva Nüsken, Kai‐Dietrich Nüsken, Julia Schipke, Miguel A. Alejandre Alcazar   +8 more
wiley   +1 more source

Investigation of the Effects of Fingolimod on the LPS-Induced Inflammatory Response in the HUVEC Cell Line

Pharmata
Aim: The objective of this study was to examine the impact of fingolimod on tumour necrosis factor-alpha (TNF-α) production in the context of a lipopolysaccharide (LPS)-induced inflammatory response in a human umbilical vein endothelial cells (HUVEC ...
Hamza Halıcı, Eda Yilmaz
doaj   +1 more source

Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection

Journal of Neuroinflammation, 2017
Background Fingolimod, a sphingosine-1-phosphate receptor modulator with well-described immunomodulatory properties involving peripheral immune cell trafficking, was the first oral agent approved for the treatment of relapsing remitting multiple ...
Björn Ambrosius, Kalliopi Pitarokoili, Lisa Schrewe, Xiomara Pedreiturria, Jeremias Motte, Ralf Gold   +5 more
doaj   +1 more source

Effetti cardiaci degli agonisti della sfingosina: monitoraggio in una coorte di pazienti con sclerosi multipla. [PDF]

, 2016
Fingolimod è il primo trattamento orale approvato per la Sclerosi Multipla (SM). Si tratta di un analogo della sfingosina e lega il recettore della sfingosina 1-fosfato (S1P1) bloccando cosi la fuoriuscita dei linfociti dai linfonodi riducendo gli ...
BLINOVA, YULIA
core  

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

Therapeutic Advances in Neurological Disorders, 2016
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing.
Bhupendra O. Khatri
doaj   +1 more source